Overseen byMark H Nelson, MD MBA
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Wake Forest University Health Sciences
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Approved in 2 jurisdictions
Trial Summary
What is the purpose of this trial?This trial tests if adding spironolactone to usual eye injections can help diabetic patients with specific eye issues who haven't improved with standard treatments. The goal is to reduce swelling and fluid leakage in the eye to improve vision. Spironolactone has been studied for its effects on heart failure and diabetes, showing some impact on blood glucose levels.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: Spironolactone TreatmentExperimental Treatment1 Intervention
Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).
Find a clinic near you
Research locations nearbySelect from list below to view details:
Wake Forest Baptist HealthWinston-Salem, NC
Loading ...
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor